New Partnership Revolutionizes The Biotech Scene

Recently, global biotech startup Arcensus GmbH, a digital healthcare and diagnostics company, received a significant financial investment from Mittelstandische Beteiligungsgesellschaft Mecklenburg-Vorpommern (MBMV). 

With this, the bioscience scene is revolutionized by detecting rare and frequent disorders such as cancer or heart diseases at the earliest stage now made possible.

What Does This Partnership Mean for US Citizens And The World? 

Based on Whole Genome Sequencing (WGS), Arcensus GmbH makes it possible to detect rare and frequent disorders such as cancer or heart diseases at the earliest stage to start preventive and personalized treatment.

With MBMV’s single-digit million capital investment into Arcensus, expansion into the U.S. region is now also possible. This investment means the biotech scene can significantly contribute to preventing diseases and the cure of rare diseases. 

As the press release reveals, “Both partners now seek to use their accumulated experiences in the field of Whole-Genome Sequencing (WGS) technology in combination with a clear focus on the game-changing artificial intelligence (AI) based deep interpretation of DNA information to enable customers to get the best insight in preventable diseases.

Overall, this partnership seeks to empower individuals with genomics and medical insight to now understand and improve their health and obtain a quality of life.  

What Is WGS?

Science Direct explains what WGS is. “The analysis of the entire genomic DNA sequence of a cell at a single time, providing the most comprehensive characterization of the genome.” This has revolutionized biosciences and helps identify gene function and how these genes are involved in common and rare diseases.

Becoming more common these days, WGS has many typical applications. According to Science Direct, these include:

• A role in diagnostic microbiology and isolate characterization ( characterize a clinical isolate, informing on the likely species and/or subtype and allowing phylogenetic placement of a given sequence relative to an existing set of isolates)
• A role in antimicrobial resistance (AMR) profiling
• Assisting with the establishment of the sources of recurrent infections and between-patient transmissions. 
• Providing case studies and additional information, somewhat replacing the knowledge obtained through standard clinical microbiology techniques.
• WGS-based strain identification and lineage identification
• Assists in the prediction of the pathogen’s phenotype 
• Assists with the reconstructing of outbreaks within hospitals and the community across a diversity of taxa 
• Assists in elucidating patterns of infection, molecular surveillance, and real-time tracking of infectious diseases
• Used as a useful diagnostics tool for its ability to rapidly inform treatment

Most of all, in a time of a global pandemic and COVID, WGS is a vital tool in which to aid the medical world in learning, discovering and understanding infections, diseases, and illnesses.

Who Is Arcensus? 

Arcensus is a digital healthcare and diagnostics company that empowers people to take control of their health. The company provides the highest-standard, secure, trusted, and comprehensive medical service based on Whole Genome Sequencing. It further analyses the complete genetic information in human DNA. It identifies reasons for vague symptoms with the help of cutting-edge technology, including artificial intelligence. The detailed medical report suggests better treatment options and helps individuals take preventive measures to live a healthier and longer life. 

Who Is Mittelstandische Beteiligungsgesellschaft Mecklenburg-Vorpommern? 

Mittelstandische Beteiligungsgesellschaft Mecklenburg-Vorpommern (MBMV) supports the promotion of regional small and medium-sized employers (SMEs) by providing capital for the implementation of economic projects.